SCHEMBL6932035

SCHEMBL6932035

COc1ccc(C(=O)Nc2ccc(C(=O)CCC(=O)O)cc2)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.58
RAB9A P51151 4/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
ALDH1A1 P00352 5/20 0.55
CYP1A2 P05177 1/20 0.55
HPGD P15428 1/20 0.55
CYP2C19 P33261 1/20 0.55
HSD17B10 Q99714 1/20 0.55
HTT P42858 1/20 0.55
MAPT P10636 3/20 0.54
HDAC8 Q9BY41 1/20 0.52
CYP2C9 P11712 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
CYP3A4 P08684 1/20 0.51
POLB P06746 1/20 0.51
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
NR1H4 Q96RI1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6929596 0.91 HDAC8 (0.61) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL6931326 0.86 NPC1 (0.54) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL6931332 0.86 NPC1 (0.54) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL2229876 0.84 NPC1 (0.59) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL6924409 0.84 MAPT (0.70) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL6926777 0.83 NPC1 (0.71) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL16149341 0.83 NPC1 (0.74) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL5658112 0.82 MEN1 (0.57) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL14157012 0.82 NPC1 (0.66) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL6930397 0.81 KMT2A (0.63) NPC1RAB9AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624196-B2 Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders WARNER-LAMBERT COMPANY 2003-09-23 US claimed
US-6541521-B1 Particularly gelatinase A, collagenase-3, and stromelysin-1 WARNER-LAMBERT COMPANY 2003-04-01 US claimed
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 2002-10-31 US claimed
US-6624196-B2 Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders WARNER-LAMBERT COMPANY 2003-09-23 US disclosed
US-6541521-B1 Particularly gelatinase A, collagenase-3, and stromelysin-1 WARNER-LAMBERT COMPANY 2003-04-01 US disclosed
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 2002-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161050-A1 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases MMP1, MMP8, MMP13 NPC1 2628/4885RAB9A 2177/4885MEN1 3055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.